Bracket Global, LLC, Boston, Massachusetts, USA.
Sunovion Pharmaceuticals, Fort Lee, New Jersey, USA.
Int J Methods Psychiatr Res. 2018 Dec;27(4):e1729. doi: 10.1002/mpr.1729. Epub 2018 Jun 26.
Site-independent ratings surveillance assessed ratings reliability in a clinical trial.
Inter-rater reliability was assessed at the screen visit in a 6-week, double-blind, placebo-controlled study of lurasidone for the treatment of major depressive disorder (MDD) with subthreshold hypomanic ("mixed") symptoms (clinicaltrials.gov NCT01421134). Site-based Montgomery-Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) interviews were paired with 184 site-independent ratings derived from audio-digital recordings.
The paired MADRS and YMRS scores were highly correlated (r = 0.708 and 0.885, respectively) and generated minimal scoring discordance. The surveillance program identified 14 MADRS scores (7.6% of this sample) that were below the study entry criterion (MADRS ≥26) and resulted in screen failure. When present, paired scoring discordance was associated with symptom severity, interview length, interview quality, and the level of patient cooperation. Higher severity scores (MADRS ≥40 and YMRS ≥15) were associated with greater paired scoring discordance. Further, MADRS scores <30 and short MADRS interviews conducted in ≤12 min revealed significantly more pairs of discordant outliers (p = 0.04 and 0.009, respectively).
The findings suggest that MDD patients with mixed features can be reliably assessed, that paired site-based and site-independent assessments were generally concordant, and that ratings surveillance may reinforce ratings precision.
独立于地点的评分监测评估了临床试验中的评分可靠性。
在一项为期 6 周、双盲、安慰剂对照的研究中,对伴有阈下轻躁狂(“混合”)症状的重度抑郁症(MDD)患者进行了 lurasidone 治疗,在筛选访视时评估了组间可靠性(clinicaltrials.gov NCT01421134)。基于地点的蒙哥马利-阿斯伯格抑郁评定量表(MADRS)和 Young 躁狂评定量表(YMRS)访谈与 184 个源自音频数字化录音的独立地点评分相配对。
配对的 MADRS 和 YMRS 评分高度相关(r 值分别为 0.708 和 0.885),且评分差异极小。监测计划识别出 14 个 MADRS 评分(该样本的 7.6%)低于研究入组标准(MADRS≥26),导致筛选失败。当存在配对评分差异时,其与症状严重程度、访谈时长、访谈质量和患者合作程度相关。更高的严重程度评分(MADRS≥40 和 YMRS≥15)与更大的配对评分差异相关。此外,MADRS 评分<30 和 MADRS 访谈时间≤12min 的情况,显示出明显更多的配对异常值(p 值分别为 0.04 和 0.009)。
这些发现表明,伴有混合特征的 MDD 患者可以进行可靠评估,基于地点和独立地点的配对评估通常是一致的,并且评分监测可能会增强评分的精准性。